Published in
Taylor and Francis Group, Expert Review of Cardiovascular Therapy, 1(21), p. 5-13, 2022
DOI: 10.1080/14779072.2023.2159811
Links
Tools
An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 